CSFluids, NMT Neurosciences Co-Developing Shunt To Treat Alzheimer's
This article was originally published in The Gray Sheet
Executive Summary
CSFluids, Inc. is in discussions with FDA about expanding an on-going clinical trial of the firm's Cognishunt system for the treatment of Alzheimer's disease.